Peer-Reviewed Publication

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

View

Poster

Increasing DNA Encoded Library Screening Resolution Using HT-SPR

View

Application Note

High resolution FcRn IC50 potency measurements using the Carterra® LSA® platform

View

Application Note

Profiling antibody polyreactivity and polyspecificity using HT-SPR on the Carterra® LSA®

View

Webinar

The Transcendence of HT-SPR Technology Across Discovery Platforms and its Impact on Time-to-Clinic

View

Webinar

AlphaLISA and HT-SPR together can help you better understand FcRn biology

View

Peer-Reviewed Publication

A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies – January 24, 2022

View

Peer-Reviewed Publication

Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries – December 30, 2021

View

Peer-Reviewed Publication

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries – December 1, 2021

View

Webinar

Exploring Multicomponent COVID-19 Mutant Variant Analysis of Immunity Indicators in Human Serum

View

Webinar

HT-SPR Technology to Inform and Accelerate the Antibody Discovery Process

View

Webinar

Bispecific Antibodies Potently Neutralize SARS-CoV-2 Variants of Concern

View

Webinar

The Transcendence of HT-SPR Technology Across Discovery Platforms and its Impact on Time-to-Clinic

View

Peer-Reviewed Publication

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study – September 23, 2021

View